Schrodinger (NASDAQ:SDGR – Get Free Report) and Aclarion (NASDAQ:ACON – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.
Risk & Volatility
Schrodinger has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500.
Insider & Institutional Ownership
79.0% of Schrodinger shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 10.1% of Schrodinger shares are owned by insiders. Comparatively, 0.0% of Aclarion shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Schrodinger | -22.02% | -18.12% | -9.07% |
| Aclarion | -10,242.78% | -62.91% | -59.33% |
Earnings and Valuation
This table compares Schrodinger and Aclarion”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Schrodinger | $255.87 million | 9.42 | -$103.26 million | ($0.79) | -41.33 |
| Aclarion | $83,769.00 | 60.17 | -$7.23 million | ($7.40) | -0.24 |
Aclarion has lower revenue, but higher earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and price targets for Schrodinger and Aclarion, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Schrodinger | 1 | 3 | 4 | 0 | 2.38 |
| Aclarion | 1 | 0 | 1 | 0 | 2.00 |
Schrodinger currently has a consensus target price of $26.67, suggesting a potential downside of 18.32%. Aclarion has a consensus target price of $7.50, suggesting a potential upside of 328.82%. Given Aclarion’s higher possible upside, analysts clearly believe Aclarion is more favorable than Schrodinger.
Summary
Schrodinger beats Aclarion on 10 of the 14 factors compared between the two stocks.
About Schrodinger
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
About Aclarion
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Receive News & Ratings for Schrodinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrodinger and related companies with MarketBeat.com's FREE daily email newsletter.
